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Paracetamol is commonly used to control mild-to-moderate pain or to reduce opioid exposure as part of
multimodal analgesia, and is the only compound recommended to treat fever in neonates.
Paracetamol clearance is lower in neonates than in children and adults. After metabolic conversion,
paracetamol is subsequently eliminated by the renal route. The main metabolic conversions are
conjugation with glucuronic acid and with sulphate. In the urine of neonates sulphated paracetamol
concentration is higher than the glucuronidated paracetamol level, suggesting that sulfation prevails
over glucuronidation in neonates. A loading dose of 20 mg/kg followed by 10 mg/kg every 6 hours of
intravenous paracetamol is suggested to achieve a compartment concentration of 11 mg/L in late preterm
and term neonates. Aiming for the same target concentration, oral doses are similar with rectal
administration of 25 to 30 mg/kg/d in preterm neonates of 30 weeks’ gestation, 45 mg/kg/d in preterm
infants of 34 weeks’ gestation, and 60 mg/kg/d in term neonates are suggested. The above-mentioned
paracetamol doses for these indications (pain, fever) are well tolerated in neonates, but do not result in a
significant increase in liver enzymes, and do not affect blood pressure and have limited effects on heart
rate. In contrast, the higher doses suggested in extreme preterm neonates to induce closure of the patent
ductus arteriosus have not yet been sufficiently evaluated regarding efficacy or safety. Moreover, focussed
pharmacovigilance to explore the potential causal association between paracetamol exposure during
perinatal life and infancy and subsequent atopy is warranted.
& 2014. The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Introduction
Paracetamol, N-acetyl-p-aminophenol (also known as acetami-
nophen), is a readily available, over-the-counter antipyretic and
analgesic compound. It is the most often prescribed drug to treat
mild-to-moderate pain or fever in infants, including neonates, and
can be administered by different routes (ie, oral, rectal, or intra-
venous). It has analgesic and antipyretic activity, but has only very
modest peripheral anti-inflammatory properties.1–3 In its thera-
peutic concentration range, paracetamol is metabolized by the liver
to paracetamol-glucuronide (47%–62%) and paracetamol-sulphate
(25%–36%) as main metabolites, and subsequently eliminated by
the renal route in adults. Only 1% to 4% is excreted unchanged in
urine, and about 8% to 10% of paracetamol is oxidized to 3-hydroxy-
paracetamol and the (hepatic) toxic metabolite N-acetyl-p-benzo-
quinone-imine (NAPQI).4 Maturation-related changes in paraceta-
mol disposition, metabolic, and elimination clearance occur
throughout childhood, but are most prominent in early life.5,6
Neonates have an overall lower paracetamol metabolic and elim-
ination clearance capacity, and the between-subject variability is
explained by covariates such as size or weight, organ function, or
disease characteristics.7–9 Compared with other drugs, a relevant
body of evidence on pharmacokinetic properties and disposition of
paracetamol in term and preterm neonates has been reported
following intravenous and enteral (oral, rectal) administration.
Despite this, there is still relevant variability in dosing suggestions
as retrieved in reference textbooks or websites (Table I).10–13
Although intravenous paracetamol administration remains off
label for specific subpopulations (eg, limited to term neonates, or
children younger than age 2 years in the United States) in many
countries, these formulations are increasingly used in neo-
nates.8,14,15 The registered dose is 7.5 mg/kg q6h for term neonates
up to infants weighing 10 kg. A dose of 15 mg/kg q6h (max daily
dose 60 mg/kg) is recommended between 10 and 40 kg body
weight. In clinical practice, a loading dose (20 mg/kg) and higher
maintenance doses are suggested (Table I) and have been eval-
uated in regard to efficacy and safety.14,15
Effective and safe drug administration in neonates should
consider the evolving physiologic characteristics (eg, maturation
and disease) of a newborn who will receive the drug and
pharmacokinetic and pharmacodynamic properties of a given
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drug. Consequently, drug disposition in neonates is as diverse as
the neonates who are admitted to our neonatal intensive care
units.16,17 This is also true for paracetamol. Using a systematic
bibliographic search strategy, we aim to provide an overview on
the pharmacokinetic and pharmacodynamic properties of para-
cetamol in neonates. This will be followed by a discussion with
specific emphasis on newly emerging issues related to potential
effects (patent ductus arteriosus [PDA]) and side effects (atopy and
emerging biomarkers).
Literature Search
Our literature search was performed using PubMed and
EMBASE databases as search engines. The following key words
were used: pharmacokinetics paracetamol/acetaminophen neonate,
metabolism paracetamol/acetaminophen neonate, and effects para-
cetamol/acetaminophen neonate. The reference list of each article
was read carefully, and the selected references were examined.
Results
Pharmacokinetic properties and metabolism of paracetamol in
neonates
Intravenous
The most recently reported pooled study on intravenous para-
cetamol pharmacokinetic properties was based on a population
pharmacokinetic analysis of 3 published studies, resulting in 943
paracetamol observations in 158 neonates (27–45 weeks post-
menstrual age [PMA]). There were only 58 preterm neonates, of
whom 21 were extreme preterm, 19 had a birth weight lower than
1500 g, and 31 were small for gestational age.8 A 2-compartment
linear disposition model with first-order elimination fitted best to
analyse time-concentration points. The volume of distribution was
70.4 L/70 kg and the clearance increased from 2.85 L/h per 70 kg at
27 weeks to reach 7.05 L/h per 70 kg by 42 weeks PMA.8 Weight
was the major covariate (57.5% of variance). Clearance expressed as
milligrams per kilogram per hour increased only slightly with PMA
(0.138 L/kg/h at 28 weeks PMA to 0.167 L/kg/h at 44 weeks PMA),
and contributes to only 2.2% of variance. High unconjugated
bilirubin levels only contributed an additional 1.2%. Based on this
pooled analysis, it was concluded that size (predicted by weight)
was the major covariate of clearance. We hereby mainly confirmed
earlier clearance estimates in a further extended cohort of (pre)
term neonates. Paracetamol clearance in neonates—described using
allometric scaling—was one-third of the mature value reported in
adults (16.2 L/h/70 kg).6,8 Clearance maturation is slow before age
40 weeks PMA and subsequently matures rapidly to reach 90% of
adult capacity at 1 year of life.6,8 In addition, the distribution
volume was higher in early infancy when compared with other
pediatric populations.6,8 The volume of distribution decreased from
27 weeks PMA (0.64 L/kg) to reach a mature value from 6 months
of age (0.4–0.45 L/kg) onward. The increased volume of distribution
in neonates supports the use of a larger initial dose (loading dose)
of intravenous paracetamol in neonates if one aims to attain a given
paracetamol threshold concentration sooner (ie, 410–11 mg/L6,8)
because a higher distribution volume results in a proportionally
lower peak concentration,8,16 as reflected in Table I.
Finally, based on the pooled analysis, a mean paracetamol
serum concentration of 11 mg/L was predicted in neonates aged
28 to 44 weeks PMA given a standard dose of 10 mg/kg/6 h
intravenous paracetamol. In Figure 1, all pooled time-
concentration observations collected in the Leuven cohorts are
provided.8,18,19 However, data of this drug in extreme preterm
neonates were still limited. It is encouraging that since this pooled
analysis, additional data have been reported or have been col-
lected. This includes observations in a cohort of very preterm
infants (o32 weeks gestational age) (N ¼ 15). Repeated dosing
(7.5 mg/kg q6h) resulted in median paracetamol levels of 10 mg/L
Table I
Dosing suggestions for paracetamol for (pre)term neonates as retrieved in refer-
ence sources.
Source Administration route Suggested dose
Neofax10
Oral Loading dose 20–25 mg/kg
Maintenance 12–15 mg/kg/dose
Interval q6h in term neonates
q8h in preterm neonates
Z32 wk PMA
q12h in preterm neonates
o32 wk PMA
Rectal Loading dose 30 mg/kg
Maintenance 12–18 mg/kg/dose
q6h in term neonates
q8h in preterm neonates
Z32 wk PMA
q12h in preterm neonates
o32 wk PMA
Intravenous No suggestions
provided
BNFc11
Oral Loading dose 20 mg/kg
Maintenance 10–15 mg/kg/dose
q6–8 h in Z32 wk
q8–12h in o32 wk PMA
Z32 wk PMA, max 60 mg/kg/d
o32 wk PMA, max 30 mg/kg/d
Rectal Loading dose 30 mg/kg in Z32 wk
Maintenance 20 mg/kg in o32 wk
20 mg/kg q8h (max 60 mg/kg/d)
Z32 wk PMA
15 mg/kg q12h (max 30 mg/kg/d)
in o32 wk
Intravenous Loading dose No suggestions provided
Maintenance 7.5 mg/kg, q4-6 h, max 30 mg/kg/
d when o10 kg, and limited to
term neonates
Neonatal formulary12
Oral Loading dose 24 mg/kg
Maintenance 12 mg/kg/dose
q4h in Z32 wk PMA, q8h in
o32 wk
Rectal Loading dose 36 mg/kg
Maintenance 24 mg/kg, q8h in term neonates
No advice in preterm neonates
Intravenous Loading dose 20 mg/kg, irrespective of age
Maintenance 15 mg/kg, q6h in term cases
12.5 mg/kg, 31–36 wk PMA
10 mg/kg, r30 wk PMA
Dutch formulary13
Oral Loading dose Not sufficiently supported by
clinical evidence
Maintenance 60 mg/kg/d, 432 wk PMA
30 mg/kg/d, 28–32 wk PMA
Rectal Loading dose 30 mg/kg, o32 wk PMA
Maintenance 20 mg/kg, 28–32 wk PMA
20 mg/kg, q8h in term neonates
20 mg/kg, q12h in preterm
neonates
Intravenous Off label in preterm neonates
Loading dose 20 mg/kg, irrespective of age
Maintenance 10 mg/kg, max 40 mg/kg/d, in
term cases
10 mg/kg, max 30 mg/kg/d, 31–
36 wk PMA
10 mg/kg, max 20 mg/kg/d, o31
wk PMA
PMA ¼ postmenstrual age (in weeks).
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at steady state, quite similar to the levels aimed for in the pooled
analysis.20 A preliminary analysis of a repeated intravenous para-
cetamol (15 mg/kg) pharmacokinetic study (89 samples in 10
patients) conducted in the United States (National Institute of
Child Health and Human Development [No. R01HD060543])
resulted in a median clearance estimate of 0.151 L/kg/h and a
median distribution volume of 1.21 L/kg with weight as the most
relevant covariate.21
Paracetamol either undergoes sulfation and glucuronida-
tion,22,23 mainly by the UDP-glucuronosyltransferase 1A6 and
to lesser extent the UDP-glucuronosyltransferase 1A9 isoenzyme.
A progressive increase in the contribution of glucuronidation
to paracetamol elimination with increasing age throughout
childhood has been described.22–24 Maturation-related aspects of
intravenous paracetamol metabolism in neonates were explored
based on quantification of paracetamol-glucuronide (APAP-G),
paracetamol-sulfate (APAP-S), and free paracetamol in 147 urine
samples of 23 neonates during repeated administration of intra-
venous propacetamol. The median molar contribution of APAP-G
to overall urine paracetamol (APAP-G þ APAP-S þ free para-
cetamol) elimination was 14% (range ¼ 1%–53%). Covariates of this
APAP-G/total amount of paracetamol (APAP-T) (APAP-G + APAP-S
+ free paracetamol) (G/T) ratio were postnatal age, postmenstrual
age, and repeated administration.23 The median urinary APAP-G/
APAP-S (G/S) ratio was 0.27.23 van Ganzewinkel et al20 also
generated data on paracetamol metabolism. Based on urine
collections, it was confirmed that both glucuronidation and
sulfation elimination increased with repeated administration.
The G/S ratio in this preterm cohort was 0.08, reflecting the
influence of prematurity on paracetamol glucuronidation capacity.
Moreover, plasma glutathione remained stable during repeated
exposure.20 This suggests that repeated paracetamol administra-
tion had no effect on the glutathione plasma levels in the preterm
neonate, potentially reflecting glutathione stores
Enteral
A pooled analysis on the developmental pharmacokinetic proper-
ties of enteral (ie, oral and rectal) paracetamol in premature neo-
nates and infants was performed by Anderson et al.5 A population
pharmacokinetic analysis of paracetamol time-concentration profiles
was studied in 283 children (n ¼ 124 aged r6 months). Neonates
and infants were given either single or multiple doses of 4 different
formulations: oral elixir, rectal solutions, or triglyceride or capsular
suppository. The median postnatal age of children younger than age
6 months was 1 day (range ¼ birth–6 months), median
postmenstrual age was 40 weeks (range ¼ 28–64 weeks), and
median weight was 3.1 kg (range ¼ 1.2–9.0 kg).
Standardized to a 70-kg person using allometric “1/4 power”
models, median clearance was 12.5 L/h (44%), and the volume of
distribution was 66.6 L (20%). Paracetamol clearance increased from
28 weeks PMA (0.74 L/hour/70 kg) with a maturation half-life of
11.3 weeks to reach 10.8 L/h/70 kg at 60 weeks PMA. The absorption
half-life for the oral elixir was 0.21 hours (120%) with a lag time of
0.42 hours (70%), but absorption was further delayed (2 hours) in
premature neonates during the first days of life. Absorption lag time
was negligible by rectal route for all 3 formulations. The bioavail-
ability of the capsule suppository relative to elixir decreased with
age from 0.92 (22%) at age 28 weeks to 0.86 at age 2 years, whereas
the triglyceride base formulation decreased from 0.86 (35%) at age
28 weeks to 0.5 at age 2 years. The relative bioavailability of the
rectal solution was 0.66. Based on these estimates, it was concluded
that a mean steady state target concentration 10 mg/L at trough
can be achieved by an oral dose of 25 mg/kg/d in premature
neonates at age 30 weeks PMA, 45 mg/kg/d at age 34 weeks
PMA, and 60 mg/kg/d at term age.5 Similar to the estimates for
intravenous pharmacokinetic properties, the volume of distribution
decreased exponentially with a maturation half-life of 11.5 weeks
from 109.7 L/70 kg at age 28 weeks after conception to 72.9 L/70 kg
by age 60 weeks PMA. Finally, Van Lingen et al9 also generated data
on paracetamol metabolism using urinary metabolite excretion.
Similar to the observations following intravenous administration,
paracetamol sulphate was the main metabolite, with a mean molar
G/S ratio of 0.12 (28–32 weeks PMA) and 0.28 (32–36 weeks PMA),
respectively.9,23 To further reflect the influence of age on glucur-
onidation capacity, the G/S ratio in paracetamol metabolites
retrieved in urine in term neonates was 0.2722 and 0.344 following
a single oral paracetamol administration.
Clinical indications for paracetamol
Fever
There are few trials that have directly compared the antipyretic
properties of paracetamol against placebo or physical methods.25
Although fever is 1 of the most common manifestations of illness
in children, this symptom is much less common in newborns.
Consequently, specific reports in newborns (ie, first 28 days of life)
on temperature reduction after paracetamol administration are
very limited, whereas reports from early infancy onward are much
more common, often in the setting of postimmunization fever.1 As
part of a study on thermodynamics in 99 neonates exposed to
intravenous paracetamol, 6 cases with fever were included. In
neonates with fever (437.81C), the median decrease (–0.81C) was
more prominent during the first 2 hours after administration.
Individual trends over time after intravenous paracetamol (20 mg/
kg) administration are provided in Figure 2.26 In neonates (n ¼
93) with normothermia, paracetamol administration had no effect
on the body temperature and hypothermia was not observed in
this cohort, but has been reported in both children27 and
adults.1,3,28
Pain
Adequate management of pain in neonates is a major issue in
contemporary neonatal care. In an attempt to avoid opioids, there
is an emerging use of paracetamol.29 However, we should be
aware of the difference in currently available evidence to support
the use of paracetamol for either procedural versus posttraumatic
or postsurgery pain in neonates. In essence, the data on para-
cetamol analgesia during procedures are limited, but suggest an
overall poor analgesic effect for procedural pain relief. In a
randomized, placebo-controlled study, Shah et al30 documented
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Figure 1. Time-concentration points for paracetamol as pooled time-concentration
observations as collected in the Leuven cohorts,8,18,19 reflecting a median para-
cetamol concentration of about 10 mg/L using the dosing regimens as suggested in
the literature13,36 (ie, loading dose of 20 mg/kg irrespective of postmenstrual age,
maintenance dose of 10 mg/kg, q6-8-12 h).
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that paracetamol administration (oral, 20 mg/kg; n ¼ 75) was not
effective to blunt pain expression related to heel lancing. Para-
cetamol administration (oral, 15 mg/kg) was not found to ameli-
orate the immediate postoperative pain of circumcision, either,
although it provided some pain reduction afterward.31 The effect
of paracetamol administration (rectal, 20 mg/kg; n ¼ 122) in
neonates following vacuum extraction was documented by Van
Lingen et al32 in a randomized, placebo-controlled trial study
design. A single dose of paracetamol significantly improved
drinking behavior, but did not result in a significant change in
objective pain scores and there were no positive effects following
repeated administration. Using a preemptive approach in 123 term
neonates after assisted delivery, infants had low pain scores
immediately after birth, irrespective of paracetamol administra-
tion. However, paracetamol administration (rectal, 20–25 mg/kg;
n ¼ 123) was associated with a more pronounced stress response
during heel lancing on Day 2 to 3.33
Although effective analgesia in neonates is still in part ham-
pered by a paucity of pharmacodynamic data, there are published
data on both a pharmacokinetic/pharmacodynamic model (mono-
therapy or mild-to-moderate pain) as well as the morphine-
sparing effect of coadministration of paracetamol in neonates
and young infants following noncardiac surgery. In an attempt to
provide evidence for analgesic effectiveness of intravenous para-
cetamol (loading dose ¼ 20 mg/kg) in neonates, pain scores after
an intravenous paracetamol loading dose (www.ClinicalTrials.gov
identifier: NCT00969176) were analyzed using repeated measures
ANOVA and an Emax model with a delayed response compart-
ment.34 Using repeated measures ANOVA, there was a trend (P ¼
0.02) for lower pain scores within 30 minutes after administration,
with a slight increase in pain scores from 5 hours onward
(Figure 3).34 An Emax model had a maximum effect of 4.15 out
of 14 pain units, an effective concentration to have 50 % of the
maximal effect (EC50) of 2.07 mg/L, and the equilibration half time
between plasma and effect site was 1.58 hours. Based on these
observations, it was concluded that intravenous paracetamol is
effective for moderate pain.33 An effect compartment concentra-
tion of 10 mg/L (loading dose ¼ 20 mg/kg) is associated with a
pain score reduction of 3.4 units, suggesting similarities in the
paracetamol effect compartment concentration in neonates com-
pared with children.34–36 Further studies should focus on both
pharmacokinetic and pharmacodynamic data in different pain
models to unveil correct dosing and correct indications.
It has recently been documented that paracetamol does result
in a clinically relevant reduction in morphine consumption (–66%)
when integrated in multimodal analgesia (morphine plus para-
cetamol).37 The cumulative median morphine dose in the first 48
hours postoperatively after an initial loading dose (100 μg/kg) in all
neonates at the end of surgery was 121 μg/kg (interquartile range
¼ 99–264 μg/kg) in the paracetamol group (n ¼ 33; 4  7.5 mg/
kg/d) and 357 μg/kg (interquartile range ¼ 220–605 μg/kg) in the
morphine group (n ¼ 38). The between-group difference was 66%
(95% CI, 34%–109%) lower in the paracetamol group, whereas pain
scores and adverse effects were not significantly different between
both groups.36 The morphine-sparing effect of paracetamol, ini-
tially described in children and adults, has hereby been confirmed
in neonates.3,37,38
Observations on safety and tolerance of paracetamol in neonates
Issues on safety and tolerance of paracetamol mainly relate to
either hepatotoxicity or hemodynamic effects. For both, data on
neonates are available in the public domain. The hepatoxicity is
not a direct effect from paracetamol itself, but relates to 1 of its
metabolites, NAPQI. NAPQI depletes the liver from glutathione that
acts as antioxidant, and directly damages cells in the liver at the
mitochondrial level, subsequently resulting in liver failure.1,39
NAPQI itself is generated in the liver through cytochrome P450
2E1 activity, an isoenzyme assumed to be less active in early
infancy.16,17
There is some literature on the systematic evaluation of liver
enzymes in cohorts of neonates exposed to paracetamol that
suggest overall good tolerance.40 The hepatic tolerance in neonates
was investigated as part of prospective studies on the pharmaco-
kinetic and pharmacodynamic properties of intravenous para-
cetamol in neonates.39 Hepatic enzyme profiles were retrieved
from 2 days before until 2 days after intravenous paracetamol
administration in 189 infants. There was no significant increase in
alanine aminotransferase, aspartate aminotransferase, or gamma-
glutamyl transferase when pretreatment observations (n ¼ 310)
were compared with observations during (n ¼ 649) or during with
after (n ¼ 173) treatment, nor was there a significant increase
during administration of paracetamol. This study on hepatic
tolerance provides evidence on safety aspects of intravenous
paracetamol in neonates. This has been further confirmed by the
absence of changes in plasma glutathione levels as reported by van
Ganzewinkel et al.20
Despite the safety pattern of these prospective data, individual
cases with potential relevant hepatic toxicity related to para-
cetamol in newborns have been reported and are summarized in
Table II.41–48 Overall, the number of cases reported remains very
limited, and observed in-hospital 10-fold drug errors do not
systematically result in significant morbidity or mortality.36,45
de Maat et al3,28 reported on a cohort of adult medium-care and
intensive-care patients with intravenous paracetamol-induced
hypotension. They hereby confirmed earlier reports on hemody-
namic (side) effects of paracetamol in critically ill adults.3,28
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Figure 2. Individual trends in body temperature (1C) over time (hours) after
intravenous paracetamol (20 mg/kg) administration.26
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Figure 3. Individual pain scores following intravenous paracetamol administration
(loading dose, 20 mg/kg).34 LNPS ¼ Leuven neonatal pain scale.
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Based on prospectively collected observations in 72 neonates, only
a very modest decrease in heart rate (7 bpm) and mean arterial
blood pressure (3 mm Hg) following intravenous paracetamol
administration was observed. A minority (9%) of neonates devel-
oped hypotension (mean arterial blood pressure o postmenstrual
age in weeks, mm Hg).49 Interestingly, these neonates already had
significantly lower blood pressure before paracetamol administra-
tion. Consequently, it was concluded that in a setting of open label
administration to alleviate pain, hemodynamic effects of intra-
venous paracetamol administration in neonates remained modest
with the suggestion to be more careful in the specific setting of
impaired hemodynamic properties in neonates.
General Discussion and New Aspects of an Old Drug
Data on paracetamol pharmacokinetic/pharmacodynamic
properties in neonates are available, and suggest that the same
effect compartment concentration (10 mg/L) should be aimed
for.34,35 This means that a loading dose should be considered
(intravenous or oral 20 mg/kg, rectal 30–40 mg/kg), followed by
maintenance (intravenous or oral 10 mg/kg, rectal 1–18 mg/kg)
doses (in term neonates q6h, in preterm [o32 weeks] neonates
q8h) to compensate for differences in distribution volume and
clearance, respectively (Table I).5,8 Similar to children and adults,
paracetamol has opioid sparing (–66%) effects in neonates after
major noncardiac surgery.37 In contrast, the currently available
data on paracetamol routes and doses suggest that paracetamol is
only a poor analgesic for procedural pain relief.30,31 Data on safety
suggest that paracetamol has a good safety profile in neonates
when administered for a limited time (48–72 hours).40,49
We also would like to explore some novelties related to either
tolerance/safety (assessment of short-term toxicity by new bio-
markers and emerging issues related to long-term safety) or to
new indications (eg, PDA).
The mechanism of paracetamol-induced liver injury involves
mitochondrial dysfunction and oxidative stress.1,40 Besides
the commonly used markers of liver necrosis, newer and likely
more sensitive biomarkers of mitochondrial damage have been
suggested.40 These include plasma glutamate dehydrogenase
activity, mitochondrial DNA concentration, but also long-chain
acylcarnitines or paracetamol protein adducts have been postu-
lated to be sensitive biomarkers.40,50–53 Perturbations in long-
chain acylcarnitines in children with paracetamol exposure or
toxicity suggest that mitochrondrial injury and associated impair-
ment in the β-oxidation of fatty acids are clinically relevant as
biomarkers of paracetamol toxicity.50 Paracetamol protein adducts
are a biomarker of paracetamol metabolism, reflecting oxidation of
paracetamol and generation of the reactive metabolite N-acetyl-p-
benzoquinone imine.51,52 Similarly, higher levels of paracetamol
protein adducts correspond to liver toxicity in patients with
paracetamol-related acute liver failure. The available observations
in pediatric and adolescent patients following paracetamol over-
dose support the need for a further examination of the role of
these protein adducts as clinically relevant and specific biomarkers
of paracetamol toxicity.52 To the very best of our knowledge, none
of these biomarkers has been evaluated in newborns or young
infants.
Besides novelties related to short-term toxicity, there are also
epidemiologic studies that suggest a link between paracetamol
exposure in early infancy and the risk to develop asthma or other
atopy-related diseases similar to the link between fetal/maternal
exposure and atopy in early infancy, although not all studies come
to the same conclusions.54–57 There may be a polymorphisms-
related link between exposure and side effect. This is because
maternal antioxidant gene polymorphisms (eg, nuclear erythroid 2
p45-related factor 2 polymorphism and glutathione S-transferase)
may modify this relationship between prenatal paracetamol expo-
sure and childhood asthma, strengthening the evidence for cau-
sality.58 The same association and similar polymorphisms have
Table II
Overview on the cases of newborns exposed to potential toxic doses of paracetamol as published in the literature41–48
Author Clinical characteristics and dose Management and outcome
Isbister et al, 200141 Former preterm newborn, 37 wk PMA N-acetyl cysteine IV þ activated charcoal transient increase in prothrombin
time, no hepatic enzymatic abnormalities, full recovery55 days postnatal age, 2.2 kg
Oral paracetamol, 136 mg/kg
de la Pintiére et al, 200342 Term newborn, in early neonatal life N-acetyl cysteine IV
2 x intravenous (pro)pacetamol, 307 mg/kg No adverse effects were observed, Discharge Day 7
Walls et al, 200843 Term newborn, early neonatal life (Day 4) N-acetyl cysteine IV, renal and hepatic failure (liver enzymes, INR
abnormalities, hypoglycemia)Following circumcision, emesis and lethargic
Oral paracetamol, 156 þ 78 þ 78 mg/kg/d Full recovery, with discharge after 1 wk
Nevin et al, 200944 preterm newborn, 35 weeks PMA N-acetyl cysteine IV, normal liver enzymes
7 weeks postnatal age, 2.6 kg Transient INR abnormalities (1.27–1.04), vitamin K
Intravenous paracetamol, 146 mg/kg Full recovery, discharge on Day 5
MHRA, 201045 23 cases (worldwide) o1 jr No data on management reported
Intravenous paracetamol overdose one case (1 out of 23) died
Most common error: 10-fold error
Porta et al, 201246 Extreme preterm newborn, 27 weeks PMA N-acetyl cysteine IV. No changes in liver enzymes, bilirubin, or prothrombin
time. Full recovery12 d postnatal age, 940 g
Indication: Abdominal distention, sepsis
Intravenous paracetamol, 446 mg/kg
Campbell et al, 201347 Former preterm newborn, 40 wk PMA N-acetyl cysteine IV. No changes in liver enzymes, bilirubin, or prothrombin
time. Full recoveryPostnatal age 3 mo, 2.3 kg
Indication: retinal laser surgery
Intravenous paracetamol, 75 mg/kg
Bucaretchi et al, 201448 26 days old, term newborn, 3.125 kg Volume replacement, plasma, inotropics, and ventilation
Indication: “feverish and weepy” N-acetyl cysteine IV. 34 days of hospitalization
Oral, 180 mg/kg (3 d 10 mg/kg, q4h)
Not yet reported, Leuven,
2014
3-wk old term newborn, 3.5 kg N-acetyl cysteine IV. No changes in liver enzymes, bilirubin, or prothrombin
time. Full recoveryIndication: pain, posttraffic accident (cranial,
thoracic injuries)
Intravenous paracetamol: 200 mg/kg
IV ¼ intravenous, PMA ¼ postmenstrual age; INR ¼ intranational normalized ratio; blood clotting test.
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been documented for postnatal exposure. The association seems
to be more significant in genetically susceptible children, related
to antioxidant genes (eg, N-actyl transferase 2, nuclear erythroid
2 p45-related factor 2 polymorphism, and glutathione S-transferase
polymorphisms), and the effect may be mediated by eosinophilic
inflammation.59 Focussed pharmacovigilance may be needed to
further unveil the complex, potentially causal association between
paracetamol exposure and subsequent increase risk to develop
atopy.60
Symptomatic PDA is a common condition in (extreme) preterm
infants. The most frequently administrated drugs to treat this
indication are cyclooxygenase inhibitors (ie, ibuprofen and indo-
methacin) to block prostaglandin synthesis and to induce muscu-
lar constriction at the level of the ductus arteriosus. Unfortunately,
the use of these drugs is associated with relevant adverse effects,
such as renal dysfunction, intestinal bleeding, and perforation or
dysfunction of platelet aggregation.61,62 Consequently, there
remains a need for alternative treatments that result in better
closure rates or fewer adverse effects. A serendipity observation of
Hammerman et al63 linked paracetamol exposure with PDA
closure.
Since that article, case reports and case series have described
the use of oral or intravenous paracetamol in patients with
contraindications to or who had previously failed nonsteroidal
anti-inflammatory drug therapy for PDA.64 There seems to be a
publication bias, because the number of negative observations is
very limited.65 Two clinical trials compared the efficacy of oral
paracetamol (15 mg/kg q6h for 3 days) versus oral ibuprofen in 90
(o30 weeks gestational age) and 160 preterm infants (o34
weeks gestational age), respectively.66,67 Paracetamol was not
inferior to ibuprofen, with closure rates from 72.5% to 81.2%.
The paracetamol dose used in most case series and trials was a
15 mg/kg dose q6h for 3 days, much higher than commonly used
in extreme preterm neonates (Table I). Paracetamol therapy was
reported to be well tolerated, with only a few reported incidents of
elevated liver enzymes. However it should not be taken for
granted yet that paracetamol induces PDA closure. If closure is
driven by prostaglandin reduction, we should be aware that
paracetamol exerts only very modest peripheral prostaglandin-
related effects and exerts its effects mainly through the central
nervous system. Related to prostaglandin synthesis, paracetamol
inhibits peroxidase (prostaglandin G2 to prostaglandin H2 con-
version) as 1 of its mechanisms of action, but this inhibition is
competitive with the prostaglandin G2 concentration itself and
peroxides.62 Potential advantages of paracetamol may relate to the
preservation of the aggregation capacity of platelets.68
Related to paracetamol for PDA closure, we need a shift toward
a more extensive research program. Taking all the above-
mentioned results into account, this will include pharmacokinetic
properties, effectiveness, and safety. There are data on para-
cetamol pharmacokinetic properties and safety, but these data
were based on lower dosing regimens (20–40 mg/kg/24 h, 1–2
days) and were collected in more mature neonates. Consequently,
we do not have subpopulation-specific pharmacokinetic proper-
ties or safety data. Some new concepts to assess paracetamol
toxicity (acylcartinitines and paracetamol protein adducts) men-
tioned earlier in the Discussion should be integrated in such
studies.
Finally, we are unaware of any median paracetamol concen-
tration to aim for to induce closure of the ductus. Consequently,
dose-seeking studies and in vitro studies are needed to guide
dosing. A relevant in vitro observation was recently published by
El-Khuffash et al.69 Using in vitro contractibility studies, these
authors illustrated a concentration/effect profile depending on
maturation and concentration. On pressure myography, paraceta-
mol induced a concentration-dependent constriction of the ductus
arteriosus in term mice, but only up to 30% of baseline, and this
required concentrations 41 mmol/L (100 mg/L, 10-fold higher
when compared with the median level for analgesia).
Conclusions
We summarized the currently available information on para-
cetamol use in neonates. For pain and fever the long-needed data
on the pharmacokinetic and pharmacodynamic properties in (pre)
term neonates finally have been generated. In contrast, we still
need data in extreme preterm neonates. We suggest that emerging
novel evaluation tools related to safety (short- and long-term) and
to potential new indications (eg, PDA) for its use in neonates need
further studies.
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